IsoRay, Inc. (ISR)
(Delayed Data from AMEX)
$0.40 USD
+0.01 (3.62%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.41 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Perspective Therapeutics, Inc. [ISR]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral Rated - Reports Fiscal 3Q, Misses Our Reduced Numbers as the Stock Makes a New Low
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated ? Is IsoRay Dependent on Russia for Radiation?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated - IsoRay: Q2-2022: Misses Our Estimates by a Mile
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated - IsoRay: Q2-2022: Misses Our Estimates by a Mile
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated IsoRay: First Quarter 2022 Results Remain Gloomy.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated IsoRay: Growth in PC Remains Dissapointing.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral-Rated - IsoRay Feels Like Deja Vu - We Remain Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Encouraging Non-Prostate Revenue Growth; Higher $2.10 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Neutral Rated IsoRay Quarter?s Performance is Flat
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Growth in Non-Prostate Revenue; Expect Prostate Revenue Growth to Return; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
BUY: Raises Capital at the Low Lowering to Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
BUY: Raises Capital at the Low - Lowering to Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
On Track to Recovery; Blu Build and GammaTile to Drive Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Record FY3Q20 Revenues; New CMS Codes Bode Well for Adoption; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
BUY- Slow but Steady Progress as new Physician Users are up 34%
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Perspective Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Avenues for Growth in 2020; Higher $1.25 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S